Shoroq Altawalbeh

Dr. Shoroq Altawalbeh


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2019 in Pharmacy Practice
Verified
Journal Article
Open access
PDF file
AAAhmad Al-Azayzih
Ahmad Al-Azayzih
RARawan AlAmoori
Rawan AlAmoori
SAShoroq Altawalbeh
Shoroq Altawalbeh
Pharmacy Practice is a free full-text journal with a scope on the practice of pharmacy. Pharmacy Practice covers pharmaceutical care, social pharmacy, pharmacy education, process and outcome research, health promotion and education, health informatics, pharmacoepidemiology

30 October 2019 in Journal of Pharmaceutical Health Services Research
Verified
Journal Article
Open access
PDF file
SAShoroq Altawalbeh
Shoroq Altawalbeh
FAFadi Alkhateeb
Fadi Alkhateeb
OAOmar F. Attarabeen
Omar F. Attarabeen
Objectives. Obtaining informed consents from older adults is surrounded by many ethical and practical challenges. The objective of this study was to eva

8 February 2023 in Healthcare
Verified
Journal Article
Open access
PDF file
TAThamer A. Alenazi
Thamer A. Alenazi
MSMaryam Bin Shaman
Maryam Bin Shaman
DSDurria M. Suliman
Durria M. Suliman
TATurkiah Alanazi
Turkiah Alanazi
SAShoroq Altawalbeh
Shoroq Altawalbeh
MAMamoon Aldeyab
Mamoon Aldeyab
This is a single-center, retrospective, cohort study aimed to evaluate the clinical outcomes of multi-drug resistance in Acinetobacter baumannii infections (MDR-AB) in intensive care unit (ICU) patients with or without a COVID-19 infection and risk factors for blood stream infection. A total of 170 patients with MDR-AB were enrolled in the study. Of these, 118 (70%) patients were admitted to the ICU due to a COVID-19 infection. Comparing the COVID-19 and non-COVID-19 groups, the use of mechanical ventilation (98.31% vs. 76.92%, p = 0.000), the presence of septic shock (96.61% vs. 82.69%, p = 0.002), and the use of steroid (99.15% vs. 71.15%, p = 0.000) and tocilizumab therapies (33.05% vs. 0%, p = 0.000) were more prevalent and statistically more significant in patients with COVID-19 infections. The average length of the ICU stay (21.2 vs. 28.33, p = 0.0042) was significantly lower in patients with COVID-19 infections. Survival rate was 21.19% for the COVID-19 group and 28.85% for non-COVID-19 group with a p-value = 0.0361. COVID-19 status was associated with significantly higher hazards of death (HR 1.79, CI 95% 1.02–3.15, p = 0.043). Higher SOFAB (15.07 vs. 12.07, p = 0.0032) and the placement of an intravascular device (97.06% vs. 89.71%, p = 0.046) were significantly associated with the development of a bloodstream infection. Our study has shown that critically ill patients with an MDR-AB infection, who were admitted due to a COVID-19 infection, had a higher hazard for death compared to non-COVID-19 infected patients.

4 April 2024 in Vaccine
Verified
Journal Article
Closed access
SAShoroq Altawalbeh
Shoroq Altawalbeh
AWAngela R. Wateska
Angela R. Wateska
MNMary Patricia Nowalk
Mary Patricia Nowalk
CLChyongchiou J. Lin
Chyongchiou J. Lin
LHLee H. Harrison
Lee H. Harrison
KSKenneth J Smith
Kenneth J Smith

8 March 2024 in Value in Health
Verified
Journal Article
Closed access
SAShoroq Altawalbeh
Shoroq Altawalbeh
AWAngela R. Wateska
Angela R. Wateska
MNMary Patricia Nowalk
Mary Patricia Nowalk
CLChyongchiou J. Lin
Chyongchiou J. Lin
LHLee H. Harrison
Lee H. Harrison
KSKenneth J. Smith
Kenneth J. Smith

26 February 2025 in BMJ Open
Verified
Journal Article
Open access
PDF file
SAShoroq Altawalbeh
Shoroq Altawalbeh
NSNahlah MN Sallam
Nahlah MN Sallam
MAMinas Al-Khatib
Minas Al-Khatib
OAOsama Y Alshogran
Osama Y Alshogran
MAMohammad S Bani Amer
Mohammad S Bani Amer
Objective Chronic kidney disease (CKD) is associated with a high economic burden, which is exacerbated by the high susceptibility to drug-related problems (DRPs) in this patient population. This study aimed to evaluate the cost-benefit ratio of medication reconciliation supplemented with medication review for inpatients with CKD, compared with the absence of this intervention. Design This was a cost-benefit analysis conducted along with a prospective interventional study. Setting The study was conducted at two hospitals in Jordan between February and May 2023. Participants The prospective interventional study included 142 admitted patients with CKD. Interventions Patients received medication reconciliation at admission and discharge as well as medication review throughout admission. Primary and secondary outcome measures The primary outcome measures were the net benefit and the benefit-to-cost ratio of the intervention. A cost-benefit analysis was conducted from the healthcare system perspective by assessing the cost of the service (the pharmacist time required to complete the service per patient) and the economic benefit, including total and per-patient cost savings and cost avoidance. Results The total estimated cost of all DRPs in the absence of interventions (cost avoidance) was $83 052 (average of $585±308 per patient); among which $20 623 was attributed to medication discrepancies. The cost savings were estimated at –$467. The supplemented medication reconciliation service was estimated to cost $714. As a result, the estimated net benefit totalled $81 871, averaging $577 per patient, with a benefit-to-cost ratio of 115.7:1 over the 4-month study period. Conclusions Delivering a supplemented medication reconciliation service by a clinical pharmacist for patients with CKD is cost beneficial from the healthcare perspective in Jordan, an example of a low- and middle-income country. This finding further confirms the pivotal role of clinical pharmacists in multidisciplinary healthcare teams.